AYLA Ayala Pharmaceuticals Inc

Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences

REHOVOT, Israel & WILMINGTON, Del. - InvestorsHub NewsWire -- March 2, 2021 - Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Ayala management will present at three upcoming virtual investor conferences:

• H.C. Wainwright & Co. Global Life Sciences Investor Conference: Available for on-demand viewing starting Tuesday, March 9, 2021 at 7:00 am ET.
• Oppenheimer & Co. 31st Annual Healthcare Conference: Corporate Presentation on Tuesday, March 16, 2021 at 11:20 am ET.
• 33rd Annual Roth Capital Partners Conference: Fireside Chat on Wednesday, March 17, 2021 at 9:30 am ET.

A live webcast of each event may be accessed by visiting the Events & Presentations section of Ayala's website at ir.ayalapharma.com. An archived replay of each webcast will be available on the website for approximately 90 days following the presentations.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. Ayala's approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). AL101 has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations and in a Phase 2 clinical trial for patients with TNBC (TENACITY) bearing Notch activating mutations and other gene rearrangements. AL102 is currently being advanced to a Phase 2/3 clinical trials for patients with desmoid tumors (RINGSIDE). For more information, visit www.ayalapharma.com.

Contacts:

Investors:

Julie Seidel

Stern Investor Relations, Inc.

+1-212-362-1200

Julie.seidel@sternir.com

Ayala Pharmaceuticals:
+1-857-444-0553
info@ayalapharma.com